Welcome to our dedicated page for G1 Therapeutics news (Ticker: GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics stock.
G1 Therapeutics, Inc. (Nasdaq: GTHX) is a commercial-stage oncology biopharmaceutical company committed to developing next-generation therapies to improve the lives of cancer patients. The company is based in Research Triangle Park, N.C., and leverages its proprietary kinase drug discovery platform to advance a pipeline of innovative compounds. G1's flagship product, COSELA® (trilaciclib), has been approved by the FDA to decrease the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC).
In addition to COSELA, G1 Therapeutics is actively developing and evaluating trilaciclib in combination with other anti-cancer therapies. One notable project is the global, multi-center, randomized, placebo-controlled Phase 3 trial known as PRESERVE 2, which investigates trilaciclib in patients with metastatic triple-negative breast cancer (mTNBC). Preliminary results have shown promising survival benefits, indicating trilaciclib’s potential to protect bone marrow and enhance patient outcomes during cytotoxic therapy.
The company also engages in strategic partnerships to broaden its impact. For instance, G1 Therapeutics has entered agreements with companies like Pepper Bio and Jupiter Bioventures to advance the clinical development and commercialization of lerociclib, another promising CDK4/6 inhibitor. These collaborations aim to explore lerociclib's efficacy in treating various cancers, including HCC and radioprotection uses.
On the financial front, G1 Therapeutics reported revenues of $82.5 million for the full year 2023, reflecting significant growth from $51.3 million in the previous year. The company's ongoing commitment to innovation and strategic collaborations underscores its role as a key player in oncology therapeutics.
For more information, visit G1 Therapeutics and follow them on Twitter and LinkedIn.
G1 Therapeutics (GTHX) is backing a Phase 2 investigator-initiated study of trilaciclib and lurbinectedin for extensive stage small cell lung cancer (ES-SCLC). This study aims to evaluate how pre-treatment with trilaciclib may enhance lurbinectedin's efficacy while mitigating neutropenia risk. The trial involves about 30 subjects and focuses on key endpoints including grade 4 neutropenia rates, overall survival, and progression-free survival. Small cell lung cancer is aggressive with a low 5-year survival rate of 6%. G1 is committed to developing next-generation cancer therapies.
G1 Therapeutics, Inc. (GTHX) will host a webcast and conference call on November 2, 2022, at 8:30 a.m. ET to provide a corporate and financial update for Q3 2022. Participants are encouraged to join 10 minutes early and can access the call after registering.
The company, based in Research Triangle Park, N.C., focuses on developing therapies for cancer, including its first commercial product, COSELA (trilaciclib), which is being evaluated across various solid tumors. For more information, visit their website.
G1 Therapeutics has announced the successful completion of patient enrollment in the Phase 3 PRESERVE 2 trial of trilaciclib for metastatic triple negative breast cancer (TNBC). A total of 187 patients were randomized to receive trilaciclib or placebo before chemotherapy with gemcitabine and carboplatin. Trilaciclib is designed to improve survival outcomes while preserving immune function during chemotherapy. The trial has received Fast Track designation from the FDA, with interim analysis expected in late 2023. Positive results may lead to expedited regulatory approval.
On October 3, 2022, G1 Therapeutics (GTHX) granted inducement stock options for 44,300 shares and 29,400 RSUs to three new employees under the Amended and Restated 2021 Plan. The options are exercisable at $12.41 per share, the closing price on the grant date. The awards incentivize new hires and comply with Nasdaq Listing Rule 5635(c)(4). The company is focused on developing therapies to improve cancer treatment, with a commercial product, COSELA®, and a robust clinical pipeline targeting several solid tumors.
G1 Therapeutics, a commercial-stage oncology company, announced that CEO Jack Bailey and the executive team will participate in the H.C. Wainwright 24th Annual Global Investment Conference. The virtual event is scheduled for September 12, 2022, at 7:00 AM ET. A live webcast and replay will be available on the company's Events & Presentations page.
G1 Therapeutics focuses on developing therapies for cancer, notably its first product, COSELA® (trilaciclib), and is advancing a tumor-agnostic development plan targeting various solid tumors.
G1 Therapeutics (Nasdaq: GTHX) will host a virtual R&D Day titled “Innovations in Oncology: The Science of Trilaciclib” on September 15, 2022, from 9:00 a.m. to 11:00 a.m. ET. The event will discuss the development strategy for trilaciclib, a therapy aimed at improving cancer treatment outcomes. New preclinical data suggesting trilaciclib's potential synergy with other cancer therapies will be presented. Noteworthy clinicians will provide insights on its immune-based mechanism of action and its importance in treating colorectal cancer.
G1 Therapeutics announced the grant of stock options and restricted stock units (RSUs) to a newly hired employee, totaling 10,000 shares of common stock and 6,600 RSUs. This grant adheres to Nasdaq Listing Rule 5635(c)(4), serving as an inducement for employment under the Amended and Restated 2021 Inducement Equity Incentive Plan. The stock options have a strike price of $14.71, vesting over four years, while RSUs vest 25% annually over four years. G1 Therapeutics focuses on cancer therapies, including its product COSELA®.
G1 Therapeutics reported $10.6 million total revenue for Q2 2022, with $8.7 million from COSELA sales, reflecting nearly 60% vial volume growth quarter-over-quarter. The company completed pivotal Phase 3 trial enrollment for trilaciclib in metastatic colorectal cancer, and achieved key milestones in multiple clinical trials, including positive data presentations. Additionally, COSELA gained conditional approval in China, earning G1 a $13 million milestone payment. Ending Q2 2022, cash and equivalents stood at $144 million, projected to fund operations into 2024.
G1 Therapeutics (GTHX) announced the granting of stock options for 10,800 shares and 7,200 restricted stock units (RSUs) to two new employees under its Amended and Restated 2021 Inducement Equity Incentive Plan. The stock options have an exercise price of $8.14 per share and will vest over four years. This plan is aimed at attracting new talent to the company. G1 is focused on developing therapies for cancer, including the product COSELA® and has a diverse clinical pipeline.
G1 Therapeutics (Nasdaq: GTHX) announced participation in two virtual investor conferences in August 2022. On August 9, CEO Jack Bailey and his team will join the 2022 BTIG Biotechnology Conference. Interested attendees must contact their BTIG representative. Additionally, on August 10, Bailey will take part in the 2022 Wedbush Pacgrow Healthcare Conference, discussing 'Commercial Oncology' at 8:35 AM ET. A webcast of this event will be available on the Events & Presentations page.
FAQ
What is the current stock price of G1 Therapeutics (GTHX)?
What is the market cap of G1 Therapeutics (GTHX)?
What does G1 Therapeutics, Inc. specialize in?
What is COSELA® (trilaciclib)?
What is the PRESERVE 2 trial?
Where is G1 Therapeutics, Inc. located?
Who are G1 Therapeutics' key partners?
What recent financial achievements has G1 Therapeutics reported?
What is lerociclib?
How can I get more information about G1 Therapeutics?
What types of cancer are G1 Therapeutics’ therapies targeting?
What are G1 Therapeutics’ future goals?
